BRIEF—UK commits to clinical trial transparency

UK lawmakers are seeking to improve clinical trial transparency, following recommendations from the House of Commons Science and Technology committee.

A policy paper urges that research findings should be “communicated in ways that are timely, meaningful and relevant to evidence users.”

Urging a full commitment to the EU’s new clinical trials database, the UK medicines regulator will seek to align the UK fully with the transparency requirements of the regulation, to the extent permitted by the future UK-EU relationship.

The document notes that, should UK trial information and results not form part of European registers in future, the UK will “make sure this information could be published on a national basis.”